Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8607904 | 0.81 | ALDH1A1 (0.41) | ALDH1A1KDM4ERXFP1CDK2 | |
| SCHEMBL3044447 | 0.78 | ALDH1A1 (0.41) | ALDH1A1KDM4ERXFP1CDK2 | |
| SCHEMBL3054589 | 0.77 | ALDH1A1 (0.40) | ALDH1A1KDM4ERXFP1CDK2 | |
| SCHEMBL8708640 | 0.75 | ALDH1A1 (0.38) | ALDH1A1KDM4ERXFP1CDK2 | |
| SCHEMBL11498403 | 0.73 | ALDH1A1 (0.50) | ALDH1A1KDM4ERXFP1CDK2 | |
| SCHEMBL7157730 | 0.72 | ALDH1A1 (0.42) | ALDH1A1KDM4ERXFP1CDK2 | |
| SCHEMBL9617743 | 0.72 | ALDH1A1 (0.40) | ALDH1A1KDM4ERXFP1CDK2 | |
| SCHEMBL1079075 | 0.70 | ALDH1A1 (0.49) | ALDH1A1KDM4ERXFP1CDK2 | |
| SCHEMBL10910405 | 0.69 | ALDH1A1 (0.45) | ALDH1A1KDM4ERXFP1CDK2 | |
| SCHEMBL4969622 | 0.68 | KDM4E (0.38) | ALDH1A1KDM4ERXFP1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2012799-B1 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | CHIMERIX INC (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-1831235-B1 | LUNG-TARGETED DRUGS | UNIV CALIFORNIA (US) | 2013-02-20 | — | — | EP | disclosed |
| US-8318700-B2 | Lung-targeted drugs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120122818-A1 | LUNG-TARGETED DRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-17 | — | — | US | disclosed |
| US-8101745-B2 | Conjugate cidofovir, idoxuridine, vidarabine, trifluridine, acyclovir, famciclovir penciclovir, valacyclovir, ganciclovir, antiviral, antimicrobial, cancer drug of interest to glycerol ethers or glycerol phosphate ethers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-24 | — | — | US | disclosed |
| US-7994143-B2 | Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates | CHIMERIX, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100249056-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | CHIMERIX, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7749983-B2 | Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates | CHIMERIX, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-06-18 | — | — | US | disclosed |
| US-20080221061-A1 | Lung-Targeted Drugs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080009462-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | CHIMERIX, INC. (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | PNP, TYMP, ENPP1 | ALDH1A1 2448/4885KDM4E 2697/4885RXFP1 4819/4885 |
| US-20080221061-A1 | Lung-Targeted Drugs | DGKG, GK, PHOSPHO1 | ALDH1A1 4007/4885KDM4E 1694/4885RXFP1 3459/4885 |
| US-20120122818-A1 | LUNG-TARGETED DRUGS | DGKG, GK, PHOSPHO1 | ALDH1A1 4007/4885KDM4E 1694/4885RXFP1 3459/4885 |
| US-20100249056-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | PNP, TYMP, ENPP1 | ALDH1A1 1729/4885KDM4E 2435/4885RXFP1 4817/4885 |
| US-20080009462-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | PNP, TYMP, ENPP1 | ALDH1A1 1729/4885KDM4E 2435/4885RXFP1 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.